Rosalie Baardman

Rosalie Baardman

Auto-generated profile, based on publicly available information

Rosalie Baardman

University of Groningen, University Medical Center Groningen, UMCG Center of Expertise for Blistering Diseases, Department of Dermatology , Groningen

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2020 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
PDF file
RBR. Baardman
R. Baardman
VYV.K. Yenamandra
V.K. Yenamandra
JDJ.C. Duipmans
J.C. Duipmans
APAnna Pasmooij
Anna Pasmooij
MJM.F. Jonkman
M.F. Jonkman
MBM.C. Bolling
M.C. Bolling
Background: Epidermolysis bullosa (EB) is a heterogeneous group of rare and incurable genetic disorders characterized by fragility of the skin and mucosae, resulting in blisters and erosions. Several epidemiological studies in other populations have been carried out, reporting varying and sometimes inconclusive figures, highlighting the need for standardized epidemiological analyses in well‐characterized cohorts.Objectives: To evaluate the epidemiological data on EB in the Netherlands, extracted from the molecularly well‐characterized cohort in the Dutch EB Registry.Methods: In this observational study all EB‐patients that were based in the Netherlands and captured in the Dutch EB Registry between 1988 and 2018 were included. The epidemiological outcomes were based on complete diagnostic data (clinical features, immunofluorescence, electron microscopy and mutation analysis), with longitudinal follow‐up.Results: A total of 464 EB‐patients (287 families) were included. The incidence and point‐prevalence of EB in the Netherlands were 41.3 per million live births and 22.4 per million population, respectively. EB Simplex (EBS), Junctional EB (JEB), Dystrophic EB (DEB) and Kindler EB were diagnosed in 45.7%, 18.8%, 34.7% and 0.9% of the EB‐patients, respectively, with an incidence and point‐prevalence of 17.5 and 11.9 (EBS), 9.3 and 2.1 (JEB), 14.1 and 8.3 (DEB), 0.5 and 0.2 (Kindler EB). In 90.5% of the EB‐patients the diagnosis was genetically confirmed. During the investigated time period 73 EB‐patients died, 72.6% of whom as a direct consequence of their EB.Conclusion: The epidemiological outcomes of EB in the Netherlands are high, attributed to a high detection rate in a well‐organized set‐up, indicating that EB might be more common than previously assumed. These epidemiological data help to understand the extensive need for (specialized) medical care of EB‐patients and is invaluable for the design and execution of therapeutic trials. This study emphasizes the importance of thorough reporting systems and registries worldwide.

2 May 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
RBRosalie Baardman
Rosalie Baardman
MBM.C. Bolling
M.C. Bolling
Linked article: Petrof et al. Br J Dermatol 2022; 186:843–848.

1 November 2022 in British Journal of Dermatology
Verified
Journal Article
Open access
CHClara Harrs
Clara Harrs
PAPeter C van den Akker
Peter C van den Akker
RBRosalie Baardman
Rosalie Baardman
JDJosé C. Duipmans
José C. Duipmans
BHBarbara Horváth
Barbara Horváth
GDGilles F.H. Diercks
Gilles F.H. Diercks

11 March 2024 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Open access
RBR. Baardman
R. Baardman
HLH. H. Lemmink
H. H. Lemmink
VYV. K. Yenamandra
V. K. Yenamandra
SCS. Z. Commandeur‐Jan
S. Z. Commandeur‐Jan
MVM. Viel
M. Viel
PAPeter C van den Akker
Peter C van den Akker
Background: Genome diagnostics is considered gold standard diagnostics for epidermolysis bullosa (EB), a phenotypically and genetically heterogeneous group of rare disorders characterized by blistering and wounding of mucocutaneous tissues. EB is caused by pathogenic variants in genes encoding proteins of the dermo‐epidermal junction. Accurate genetic diagnosis of EB is crucial for prognostication, counselling and precision‐medicine. Genome diagnostics for EB started in 1991 with the introduction of Sanger sequencing (SS), analysing one gene at a time. In 2013, SS was superseded by next‐generation sequencing (NGS), that allow for high‐throughput sequencing of multiple genes in parallel. Several studies have shown a beneficial role for NGS in EB diagnostics, but its true benefit has not been quantified.Objectives: To determine the benefit of NGS in EB by systematically evaluating the performance of different genome diagnostics used over time based on robust data from the Dutch EB Registry.Methods: The diagnostic performances of SS and NGS were systematically evaluated in a retrospective observational study including all index cases with a clinical diagnosis of EB in whom genome diagnostics was performed between 01 January 1994 and 01 January 2022 (n = 308), registered at the Dutch EB Expertise Centre.Results: Over time, a genetic diagnosis was made in 289/308 (94%) EB cases. The diagnostic yield increased from 89% (SS) to 95% (NGS). Most importantly, NGS significantly reduced diagnostic turnaround time (39 days vs. 211 days, p < 0.001). The likelihood of detecting variants of uncertain significance and additional findings increased from 5% and 1% (SS) to 22% and 13% (NGS) respectively.Conclusions: Our study quantifies the benefit of NGS‐based methods and demonstrate they have had a major impact on EB diagnostics through an increased diagnostic yield and a dramatically decreased turnaround time (39 days). Although our diagnostic yield is high (95%), further improvement of genome diagnostics is urgently needed to provide a genetic diagnosis in all EB patients.

11 June 2024 in British Journal of Dermatology
Verified
Journal Article
Open access
PDF file
EKEva Willemijn Hélène Korte
Eva Willemijn Hélène Korte
RBRosalie Baardman
Rosalie Baardman
GPGrieteke Pool
Grieteke Pool
JDJosephina C Duipmans
Josephina C Duipmans
PAPeter C van den Akker
Peter C van den Akker
MBM.C. Bolling
M.C. Bolling
Epidermolysis bullosa (EB) concerns a heterogeneous group of rare genetic skin fragility disorders that result in chronic blistering and wounding. EB significantly impacts the daily lives of patients with EB, as well as their families. While advances in diagnostics are improving the speed and accuracy of EB diagnosis, little is known about the experiences and needs of parents and patients throughout their diagnostic journey. In this qualitative study, we explore the parent and patient perspective on the EB diagnostic trajectory to gain an in-depth understanding of their lived experiences and needs. Participants were parents of paediatric patients (n=18), and adult patients (n=8) recruited from the Dutch EB Registry. After purposive sampling, they participated in semi-structured interviews via video-calls to discuss their personal diagnostic trajectory and the subsequent impact of EB diagnosis on their (family) life. Applying a constructivist approach, a reflexive thematic analysis was executed to facilitate a dynamic and iterative process, involving inductive open coding of transcripts and constant comparison of data. Ten major themes were developed, representing three distinct groups: (i) parents of children with JEB and RDEB, (ii) parents of children with EBS and DDEB, and (iii) adult patients with localized EB. The EB diagnostic process appeared to have a diversity of emotional consequences, varying from desperation and uncertainty about the future, to clarification and confirmation. The urgent need for a timely diagnosis and accurate prognosis was emphasized, particularly by parents of children with extensive presentation. Both parents and patients expressed shortcomings in clinical practice, with severity ratings in current EB disease terminology in particular seeming to have an adverse impact on illness perception, healthcare-seeking behaviour, research participation, and engagement in peer support. This study describes the lived experience and needs of parents of children and adult patients during the diagnostic process of EB. We show an urgent need to accelerate diagnostics and imply that the EB community should continue working towards ever faster diagnosis, public awareness, and education. While guiding patients along the diagnostic journey, clinicians should focus their support strategies on tailored medical communication, while refraining from value-connoted wording.

29 April 2021 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
RBR. Baardman
R. Baardman
JBJ. Bremer
J. Bremer
GDG.F.H. Diercks
G.F.H. Diercks
SJS.Z. Jan
S.Z. Jan
HLH.H. Lemmink
H.H. Lemmink
PAPeter C van den Akker
Peter C van den Akker